Leslie Stolz
Algemeen Adviseur bij VERVE THERAPEUTICS, INC.
Profiel
Leslie Stolz is currently working as the Senior Vice President-Regulatory Affairs at Verve Therapeutics, Inc. Prior to this, Leslie worked as the Vice President-Regulatory Strategy at Syntimmune, Inc. Leslie holds a doctorate degree from Duke University and an undergraduate degree from Villanova University.
Actieve functies van Leslie Stolz
| Bedrijven | Functie | Begin |
|---|---|---|
| VERVE THERAPEUTICS, INC. | Algemeen Adviseur | 01-06-2019 |
Eerdere bekende functies van Leslie Stolz
| Bedrijven | Functie | Einde |
|---|---|---|
Syntimmune, Inc.
 Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01-01-2018 |
Opleiding van Leslie Stolz
| Duke University | Doctorate Degree |
| Villanova University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| VERVE THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Health Technology |
